CRISPR/Cas‐mediated genome editing to treat EGFR‐mutant lung cancer: a personalized molecular surgical therapy

Abstract While substantial progress has been made in the treatment of lung cancer with the development of tyrosine kinase inhibitors (TKIs) that target tumor‐driving mutations in the epidermal growth factor receptor (EGFR), nearly all patients treated with TKIs ultimately develop drug resistance due...

Full description

Saved in:
Bibliographic Details
Main Authors: Huibin Tang, Joseph B Shrager
Format: Article
Language:English
Published: Springer Nature 2016-01-01
Series:EMBO Molecular Medicine
Online Access:https://doi.org/10.15252/emmm.201506006
Tags: Add Tag
No Tags, Be the first to tag this record!